ReviewInternational journal of molecular sciences2024
Clinical Insights into MicroRNAs in Depression: Bridging Molecular Discoveries and Therapeutic Potential.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- METTL3-dependent m⁶A maturation of miR-140-3p contributes to hippocampal neuronal apoptosis through the OTX2/Wnt/β-catenin axis under chronic stress.Molecular biology reports · 2026Article
- Comparative Experimental Raman, DFT, and Chemometric Characterization of Selected Phenolic Acids: Structural and Environmental Contributions to the Vibrational Response.Molecules (Basel, Switzerland) · 2026Article
- Nanomedicine for Depression: From Blood-Brain Barrier Delivery to Neuroimmune-Barrier-Plasticity Network Reprogramming.International journal of nanomedicine · 2026Review
- MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Bridging Mind and Gut: The Molecular Mechanisms of microRNA, Microbiota, and Cytokine Interactions in Depression.Current gene therapy · 2026Review
- Nanotechnology-Enhanced MicroRNAs for Improved Diagnosis and Treatment of Major Depressive Disorder: A Comprehensive Review.Molecular neurobiology · 2025Review
- MicroRNAs as Biomarkers and Therapeutic Targets in Treatment-Resistant Depression: Unveiling Diagnostic and Treatment Pathways.Current reviews in clinical and experimental pharmacology · 2025Article
- The Role of miRNAs in the Differential Diagnosis of Alzheimer's Disease and Major Depression: A Bioinformatics-Based Approach.International journal of molecular sciences · 2025Article
- Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.Molecular neurobiology · 2025Review
- MicroRNAs: A Novel Approach for Monitoring Treatment Response in Major Depressive Disorder?Non-coding RNA · 2025Review
- MicroRNA signatures in neuroplasticity, neuroinflammation and neurotransmission in association with depression.Journal of physiology and biochemistry · 2025Review
- Fructus Arctii Mitigates Depressive Disorder via the Let-7e-Modulated Toll-Like Receptor (TLR) Signaling Pathway.Brain and behavior · 2024Article
- Review
- BDNF Modulation by microRNAs: An Update on theCells · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is a major contributor to the overall global burden of disease. The discovery of biomarkers for diagnosis or prediction of treatment responses and as therapeutic agents is a current priority. Previous studies have demonstrated the importance of short RNA molecules in the etiology of depression. The most extensively researched of these are microRNAs, a major component of cellular gene regulation and function. MicroRNAs function in a temporal and tissue-specific manner to regulate and modify the post-transcriptional expression of target mRNAs. They can also be shuttled as cargo of extracellular vesicles between the brain and the blood, thus informing about relevant mechanisms in the CNS through the periphery. In fact, studies have already shown that microRNAs identified peripherally are dysregulated in the pathological phenotypes seen in depression. Our article aims to review the existing evidence on microRNA dysregulation in depression and to summarize and evaluate the growing body of evidence for the use of microRNAs as a target for diagnostics and RNA-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.